PMID- 26304749
OWN - NLM
STAT- MEDLINE
DCOM- 20160725
LR  - 20181202
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 5
DP  - 2015 Aug 25
TI  - HCRP-1 regulates cell migration and invasion via EGFR-ERK mediated up-regulation 
      of MMP-2 with prognostic significance in human renal cell carcinoma.
PG  - 13470
LID - 10.1038/srep13470 [doi]
LID - 13470
AB  - Previous studies indicated a role of hepatocellular carcinoma-related 
      protein-1(HCRP-1) in human cancers, however, its expression pattern in renal cell 
      carcinoma (RCC) and the molecular mechanism of HCRP-1 on cancer progression have 
      not been characterized. In the present study, HCRP-1 expression was examined in a 
      RCC tissue microarray. The negative expression of HCRP-1 was significantly 
      correlated with tumor grade (P = 0.002), TNM stage (P = 0.001) and pT status 
      (P = 0.003). Furthermore, we showed a strong correlation between negative HCRP-1 
      expression and worse overall and disease-specific survival (P = 0.0003 and 
      P = 0.0012, respectively). Knockdown of HCRP-1 promoted cell migration and 
      invasion in 786-O and OS-RC-2 cell lines. HCRP-1 depletion increased matrix 
      metalloproteinase (MMP)-2 protein level, with increased extracellular 
      signal-regulatedkinase (ERK) phosphorylation, which could be reversed by ERK 
      siRNA or ERK inhibitor, PD98059. Further analysis showed that HCRP-1 knockdown 
      induced epidermal growth factor receptor (EGFR) phosphorylation. Treatment with 
      EGFR inhibitor or EGFR siRNA blocked HCRP-1-mediated up-regulation of EGFR, ERK 
      phosphorylation and MMP-2 expression. In summary, our results showed that 
      negative HCRP-1 expression is an independent prognostic factor for RCC patients 
      and promotes migration and invasion by EGFR-ERK-mediated up-regulation of MMP-2. 
      HCRP-1 may serve as a therapeutic target for RCC.
FAU - Chen, Feifei
AU  - Chen F
AD  - Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer 
      Institute, Xuzhou Medical College, Xuzhou, Jiangsu, China.
FAU - Deng, Junpeng
AU  - Deng J
AD  - Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer 
      Institute, Xuzhou Medical College, Xuzhou, Jiangsu, China.
AD  - Department of Urology, Suzhou Municipal Hospital, Suzhou, China.
FAU - Liu, Xin
AU  - Liu X
AD  - Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer 
      Institute, Xuzhou Medical College, Xuzhou, Jiangsu, China.
FAU - Li, Wang
AU  - Li W
AD  - The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China.
FAU - Zheng, Junnian
AU  - Zheng J
AD  - Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer 
      Institute, Xuzhou Medical College, Xuzhou, Jiangsu, China.
AD  - The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150825
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Endosomal Sorting Complexes Required for Transport)
RN  - 0 (VPS37A protein, human)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 3.4.24.24 (MMP2 protein, human)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
SB  - IM
EIN - Sci Rep. 2016;6:19412. PMID: 26815012
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Renal Cell/*metabolism/*mortality/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - China/epidemiology
MH  - Endosomal Sorting Complexes Required for Transport/*metabolism
MH  - ErbB Receptors/metabolism
MH  - Humans
MH  - Incidence
MH  - Kidney Neoplasms/*metabolism/*mortality/pathology
MH  - MAP Kinase Signaling System
MH  - Matrix Metalloproteinase 2/*metabolism
MH  - Neoplasm Invasiveness
MH  - Prognosis
MH  - Reproducibility of Results
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Signal Transduction
MH  - Survival Rate
MH  - Up-Regulation
PMC - PMC4548257
EDAT- 2015/08/26 06:00
MHDA- 2016/07/28 06:00
PMCR- 2015/08/25
CRDT- 2015/08/26 06:00
PHST- 2015/01/29 00:00 [received]
PHST- 2015/07/28 00:00 [accepted]
PHST- 2015/08/26 06:00 [entrez]
PHST- 2015/08/26 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
PHST- 2015/08/25 00:00 [pmc-release]
AID - srep13470 [pii]
AID - 10.1038/srep13470 [doi]
PST - epublish
SO  - Sci Rep. 2015 Aug 25;5:13470. doi: 10.1038/srep13470.